Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis

摘要: The efficacy of nabumetone was compared with that diclofenac, naproxen, ibuprofen, and piroxicam in patients osteoarthritis (OA) or rheumatoid arthritis (RA) a randomized, controlled, open-label, multicenter trial. Patients > = 18 years clinical radiographic evidence OA RA (functional class I, II, III), who provided written informed consent, were eligible. To mimic real-life therapy, no washout phase preceded randomization. Eligible assigned 3:1 ratio to receive comparator NSAID for 12 weeks. Thus total 4,411 eligible randomized (N 3,315) one the NSAIDs 1,096). Initial daily doses were: nabumetone, 1,000 mg; 100 500 1,200 piroxicam, 10 mg. Dosage increases permitted after 2-week trial period. All evaluated at baseline, 4 Of all approximately 46% had 54% OA. Demographic characteristics similar treatment groups. In OA, as effective physician patient global assessments disease activity, improving Activities Lifestyle Index, decreasing degree pain. There significant difference percentage withdrawn lack when treated NSAIDs. contrast, significantly (p < 0.02) more than pain relief, primarily due poor response ibuprofen Furthermore, fewer nabumetone-treated (8.8%) withdrew those diclofenac (10.3%), naproxen (11%), (13.5%), (13.2%). conclusion, large, open-label mimicked However, RA, NSAIDs, because efficacy.